Evidence map›Paper›PMID 41070787›Full record

ArticleCancer2025

5-fluoro-deoxyglucose PET/CT response after neoadjuvant chemotherapy predicts long-term outcomes in soft tissue sarcomas: Results from a prospective trial.

Edward Y Cheng, Andrea P Espejo Freire, Juan C Manivel, Jerry W Froelich, Brenda J Weigel, Denis R Clohisy, Christian M Ogilvie, Rich Evans, L Chinsoo Cho, Kathryn E Dusenbery and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Edward Y ChengDepartment of Orthopedic Surgery, The Masonic Cancer Center, The University of Minnesota Medical School, University of Minnesota, Minneapolis, Minnesota, USA.
Andrea P Espejo FreireDepartment of Medicine, The Masonic Cancer Center, The University of Minnesota Medical School, University of Minnesota, Minneapolis, Minnesota, USA.ORCID https://orcid.org/0000-0001-9903-0864
Juan C ManivelDepartment of Pathology and Laboratory Medicine, Minneapolis Veterans Affairs Medical Center, Minneapolis, Minnesota, USA.
Jerry W FroelichDepartment of Radiology, The Masonic Cancer Center, The University of Minnesota Medical School, University of Minnesota, Minneapolis, Minnesota, USA.
Brenda J WeigelDepartment of Oncology, St Jude Children's Research Hospital, Memphis, Tennessee, USA.
Denis R ClohisyDepartment of Orthopedic Surgery, The Masonic Cancer Center, The University of Minnesota Medical School, University of Minnesota, Minneapolis, Minnesota, USA.
Christian M OgilvieDepartment of Orthopedic Surgery, The Masonic Cancer Center, The University of Minnesota Medical School, University of Minnesota, Minneapolis, Minnesota, USA.
Rich EvansBiostatistics Core, The Masonic Cancer Center, The University of Minnesota Medical School, University of Minnesota, Minneapolis, Minnesota, USA.
L Chinsoo ChoDepartment on Radiation Oncology, The Masonic Cancer Center, The University of Minnesota Medical School, University of Minnesota, Minneapolis, Minnesota, USA.
Kathryn E DusenberyDepartment on Radiation Oncology, The Masonic Cancer Center, The University of Minnesota Medical School, University of Minnesota, Minneapolis, Minnesota, USA.
Keith M SkubitzDepartment of Medicine, The Masonic Cancer Center, The University of Minnesota Medical School, University of Minnesota, Minneapolis, Minnesota, USA.

Funding

Women's CancerP30CA077598 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Douglas Yee · 1998 to 2026
$100.4M
University of Minnesota Clinical and Translational Science Institute (UMN CTSI)UL1TR002494 · NCATS · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R, WEISDORF, DANIEL J · 2018 to 2022
$34.9M
NCATS NIH HHS UL1 TR002494NCATS NIH HHS UL1-TR002494NCI NIH HHS P30 CA077598NIH HHS P30CA077598Rein in Sarcoma Foundation
6 · The paper itself

Abstract

backgroundOnly 30%-40% of high-grade sarcomas respond to initial chemotherapy, which can have significant toxicities. Computed tomography imaging alone has limitations in evaluating treatment response. Imaging with 5-fluoro-deoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT), which evaluates tumor metabolism, offers an alternative. This study examined whether early changes in the maximum standardized uptake value (SUVmax) after neoadjuvant chemotherapy can be used to predict outcomes in high-grade sarcomas.

methodsThis prospective trial assessed whether changes in the SUVmax after one or four cycles of pegylated-liposomal doxorubicin plus ifosfamide could predict progression-free survival (PFS), overall survival (OS), and histologic response. Fifty-six patients were required for 90% power. Metabolic response was defined as a reduction ≥40% in the SUVmax from baseline after either cycle 1 (delta 1) or cycle 4 (delta 2).

resultsSixty-nine patients were enrolled (2006-2013) with a median follow-up of 8.1 years. The 10-year PFS rate was 74% versus 42% for delta 1 responders versus nonresponders (p = .0082), respectively; and 69% versus 33% for delta 2 responders versus nonresponder (p = .0015), respectively. The 10-year OS rate was 73% versus 58% for delta 1 responders versus nonresponder (p = .28), respectively; and 81% versus 37% for delta 2 responders versus nonresponder (p = .00026), respectively. Of 46 delta 1 nonresponders, 23 met criteria at delta 2. A positron emission tomography response was correlated with histologic necrosis. At last follow-up, 31 patients (44.9%) were alive and disease free, and 10 (14.5%) were alive with sarcoma. Five patients developed secondary malignancies.

conclusionsAn SUVmax reduction verified on FDG-PET/CT imaging after neoadjuvant chemotherapy was a strong predictor of long-term outcomes. Metabolic imaging at treatment completion identified responders, supporting continued therapy in initially nonresponsive patients and guiding personalized treatment strategies.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsFluorodeoxyglucose F18Positron Emission Tomography Computed TomographySarcomaAdolescentAdultAgedDoxorubicinFemaleHumansIfosfamideMaleMiddle AgedNeoadjuvant TherapyPrognosisProgression-Free SurvivalDoxorubicinFluorodeoxyglucose F18IfosfamideRadiopharmaceuticalsdoxorubicinifosfamideneoadjuvant therapypositron emission tomographyprognosissarcomasoft tissue

Identifiers

PMID41070787
PMCPMC12512503

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.